Oxcarbazepine Versus Placebo in Childhood Autism

NACompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Autism
Interventions
DRUG

Oxcarbazepine

Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.

OTHER

Placebo/sugar pill

Dosage similar to active drug

Trial Locations (1)

08854

Child and Adolescent Psychiatry at the University Behavioral Healthcare Building, UMDNJ-RWJMS, Piscataway

All Listed Sponsors
collaborator

National Alliance for Research on Schizophrenia and Depression

OTHER

lead

University of Medicine and Dentistry of New Jersey

OTHER

NCT00467753 - Oxcarbazepine Versus Placebo in Childhood Autism | Biotech Hunter | Biotech Hunter